875623313	875623313	CD	B-NP	O
|	|	NN	I-NP	O
HH	HH	NN	I-NP	O
|	|	NN	I-NP	O
59937331	59937331	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
0423738	0423738	CD	B-NP	O
|	|	CC	I-NP	O
7/24/2007	7/24/2007	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
Asthmatic	Asthmatic	JJ	I-NP	I-protein
flare	flare	NN	I-NP	I-protein
|	|	NN	I-NP	I-protein
|	|	NN	I-NP	I-protein
DIS	DIS	NNP	I-NP	I-protein
|	|	NNP	I-NP	I-protein
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
11/22/2007	11/22/2007	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Discharge	Discharge	NNP	B-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
9/25/2007	9/25/2007	CD	B-NP	O
******	******	SYM	I-NP	O
FINAL	FINAL	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
ORDERS	ORDERS	NNS	I-NP	O
******	******	SYM	O	O
BELIEU	BELIEU	NNP	B-NP	O
,	,	,	O	O
BLAINE	BLAINE	NNP	B-NP	O
878-10-93-3	878-10-93-3	CD	I-NP	O
Sant	Sant	NNP	I-NP	O
Po	Po	NNP	I-NP	O
Lualerock	Lualerock	NNP	I-NP	O
Service	Service	NNP	I-NP	O
:	:	:	O	O
MED	MED	NNP	B-NP	O
DISCHARGE	DISCHARGE	NNP	I-NP	O
PATIENT	PATIENT	NNP	I-NP	O
ON	ON	NNP	I-NP	O
:	:	:	O	O
3/26/07	3/26/07	CD	B-NP	O
AT	AT	NN	I-NP	O
04	04	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
PM	PM	NNP	I-NP	O
CONTINGENT	CONTINGENT	NNP	I-NP	O
UPON	UPON	NNP	I-NP	O
Not	Not	NNP	I-NP	O
Applicable	Applicable	NNP	I-NP	O
WILL	WILL	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
ORDER	ORDER	NNP	I-NP	O
BE	BE	NNP	I-NP	O
USED	USED	NNP	I-NP	O
AS	AS	NNP	I-NP	O
THE	THE	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
SUMMARY	SUMMARY	NNP	I-NP	O
:	:	:	O	O
YES	YES	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
JANNELL	JANNELL	NNP	B-NP	O
,	,	,	O	O
BRYON	BRYON	NNP	B-NP	O
A.	A.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
CODE	CODE	NNP	I-NP	O
STATUS	STATUS	NNP	I-NP	O
:	:	:	O	O
Full	Full	JJ	B-NP	O
code	code	NN	I-NP	O
DISPOSITION	DISPOSITION	NN	I-NP	O
:	:	:	O	O
Home	Home	NN	B-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-NP	O
services	service	NNS	I-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
ON	ON	NN	I-NP	O
ADMISSION	ADMISSION	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

AMLODIPINE	AMLODIPINE	NN	B-NP	B-protein
10	10	CD	I-NP	I-protein
MG	MG	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
QD	QD	NN	I-NP	I-protein
2	2	CD	I-NP	I-protein
.	.	.	O	O

GABAPENTIN	GABAPENTIN	NN	B-NP	B-protein
300	300	CD	I-NP	I-protein
MG	MG	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
TID	TID	NN	I-NP	I-protein
3	3	CD	I-NP	I-protein
.	.	.	O	O

HYDROCHLOROTHIAZIDE	HYDROCHLOROTHIAZIDE	NN	B-NP	B-protein
25	25	CD	I-NP	I-protein
MG	MG	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
QD	QD	NN	I-NP	I-protein
4	4	CD	I-NP	I-protein
.	.	.	O	O

PHENYTOIN	PHENYTOIN	NN	B-NP	B-protein
250	250	CD	I-NP	I-protein
MG	MG	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
BID	BID	NN	I-NP	I-protein
5	5	CD	I-NP	I-protein
.	.	.	O	O

SIMVASTATIN	SIMVASTATIN	NN	B-NP	O
20	20	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
QHS	QHS	NN	I-NP	B-protein
6	6	CD	I-NP	I-protein
.	.	.	O	O

LISINOPRIL	LISINOPRIL	NN	B-NP	B-protein
40	40	CD	I-NP	I-protein
MG	MG	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
QD	QD	NN	I-NP	I-protein
7	7	CD	I-NP	I-protein
.	.	.	O	O

ALBUTEROL	ALBUTEROL	NN	B-NP	B-protein
INHALER	INHALER	NN	I-NP	I-protein
2	2	CD	I-NP	I-protein
PUFF	PUFF	NN	I-NP	I-protein
INH	INH	NN	I-NP	I-protein
Q4H	Q4H	NN	I-NP	I-protein
8	8	CD	I-NP	I-protein
.	.	.	O	O

FLUTICASONE	FLUTICASONE	NN	B-NP	B-protein
PROPIONATE	PROPIONATE	NN	I-NP	I-protein
110	110	CD	I-NP	I-protein
MCG	MCG	NN	I-NP	I-protein
ORAL	ORAL	NN	I-NP	I-protein
INHALER	INHALER	NN	I-NP	I-protein
2	2	CD	I-NP	I-protein
PUFFS	PUFFS	NN	I-NP	I-protein
INH	INH	NN	I-NP	I-protein
BID	BID	NN	I-NP	I-protein
9	9	CD	I-NP	I-protein
.	.	.	O	O

CITALOPRAM	CITALOPRAM	NN	B-NP	B-protein
20	20	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
QD	QD	NNP	I-NP	O
MEDICATIONS	MEDICATIONS	NNP	I-NP	O
ON	ON	NNP	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
:	:	:	O	O
ALBUTEROL	ALBUTEROL	NN	B-NP	B-protein
INHALER	INHALER	NN	I-NP	I-protein
2	2	CD	I-NP	I-protein
PUFF	PUFF	NN	I-NP	I-protein
INH	INH	NN	I-NP	I-protein
Q4H	Q4H	NN	I-NP	I-protein
PRN	PRN	NNP	I-NP	I-protein
Wheezing	Wheezing	NNP	I-NP	I-protein
NORVASC	NORVASC	NNP	I-NP	I-protein
-LRB-	-LRB-	NNP	I-NP	I-protein
AMLODIPINE	AMLODIPINE	NNP	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
10	10	CD	I-NP	I-protein
MG	MG	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
DAILY	DAILY	NN	I-NP	I-protein
HOLD	HOLD	NN	I-NP	I-protein
IF	IF	NN	I-NP	I-protein
:	:	:	O	O
SBP	SBP	NN	B-NP	B-protein
<	<	SYM	O	O
90	90	CD	B-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Avoid	Avoid	NNP	I-NP	O
grapefruit	grapefruit	NN	I-NP	O
unless	unless	IN	B-SBAR	O
MD	MD	NN	B-NP	B-DNA
instructs	instruct	NNS	I-NP	I-DNA
otherwise	otherwise	RB	B-ADVP	O
.	.	.	O	O

CIPROFLOXACIN	CIPROFLOXACIN	NN	B-NP	B-protein
250	250	CD	I-NP	I-protein
MG	MG	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
Q12H	Q12H	NN	I-NP	I-protein
X	X	SYM	B-VP	I-protein
3	3	CD	B-NP	I-protein
doses	dose	NNS	I-NP	I-protein
Starting	Start	VBG	B-VP	I-protein
Today	Today	NN	B-NP	I-protein
-LRB-	-LRB-	NN	I-NP	I-protein
3/10	3/10	CD	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
Food/Drug	Food/Drug	NNP	I-NP	I-protein
Interaction	Interaction	NNP	I-NP	I-protein
Instruction	Instruction	NNP	I-NP	I-protein
Administer	Administer	NNP	I-NP	I-protein
iron	iron	NN	I-NP	I-protein
products	product	NNS	I-NP	I-protein
a	a	DT	B-NP	O
minimum	minimum	NN	I-NP	O
of	of	IN	B-PP	O
2	2	CD	B-NP	O
hours	hour	NNS	I-NP	O
before	before	IN	B-PP	O
or	or	CC	I-PP	O
after	after	IN	I-PP	O
a	a	DT	B-NP	O
levofloxacin	levofloxacin	NN	I-NP	O
or	or	CC	I-NP	O
ciprofloxacin	ciprofloxacin	NN	I-NP	O
dose	dose	NN	I-NP	O
dose	dose	NN	I-NP	O
If	If	IN	B-SBAR	O
on	on	IN	B-PP	O
tube	tube	NN	B-NP	O
feeds	feed	NNS	I-NP	O
,	,	,	O	O
please	please	VB	B-VP	O
cycle	cycle	NN	B-NP	B-protein
-LRB-	-LRB-	NN	I-NP	I-protein
hold	hold	VBP	B-VP	O
1	1	CD	B-NP	O
hr	hr	NN	I-NP	O
before	before	IN	B-PP	O
to	to	TO	B-PP	O
2	2	CD	B-NP	O
hr	hr	NN	I-NP	O
after	after	IN	B-PP	O
-RRB-	-RRB-	NN	B-NP	B-protein
Take	Take	NN	I-NP	I-protein
2	2	CD	B-NP	I-protein
hours	hour	NNS	I-NP	I-protein
before	before	IN	B-PP	O
or	or	CC	B-NP	O
2	2	CD	I-NP	O
hours	hour	NNS	I-NP	O
after	after	IN	B-PP	O
dairy	dairy	NN	B-NP	O
products	product	NNS	I-NP	O
.	.	.	O	O

CITALOPRAM	CITALOPRAM	NN	B-NP	B-DNA
20	20	CD	I-NP	I-DNA
MG	MG	NNP	I-NP	I-DNA
PO	PO	NNP	I-NP	I-DNA
DAILY	DAILY	NNP	I-NP	I-DNA
FLOVENT	FLOVENT	NNP	I-NP	I-DNA
HFA	HFA	NNP	I-NP	I-DNA
-LRB-	-LRB-	NNP	I-NP	I-DNA
FLUTICASONE	FLUTICASONE	NNP	I-NP	I-DNA
PROPIONATE	PROPIONATE	NNP	I-NP	I-DNA
INH	INH	NNP	I-NP	I-DNA
-RRB-	-RRB-	NNP	I-NP	I-DNA
110	110	CD	I-NP	I-DNA
MCG	MCG	NNP	I-NP	I-DNA
INH	INH	NNP	I-NP	I-DNA
BID	BID	NNP	I-NP	I-DNA
Instructions	Instruction	NNPS	I-NP	I-DNA
:	:	:	O	O
2	2	CD	B-NP	O
puffs	puff	NNS	I-NP	O
twice	twice	RB	B-NP	O
daily	daily	RB	I-NP	O
NEURONTIN	NEURONTIN	NN	I-NP	B-protein
-LRB-	-LRB-	NN	I-NP	I-protein
GABAPENTIN	GABAPENTIN	NN	I-NP	I-protein
-RRB-	-RRB-	HYPH	B-NP	O
600	600	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
TID	TID	NN	I-NP	O
HYDROCHLOROTHIAZIDE	HYDROCHLOROTHIAZIDE	NN	I-NP	O
25	25	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
DAILY	DAILY	NN	I-NP	O
HOLD	HOLD	NN	I-NP	O
IF	IF	NN	I-NP	O
:	:	:	O	O
SBP	SBP	NN	B-NP	O
<	<	SYM	O	O
90	90	CD	B-NP	O
LISINOPRIL	LISINOPRIL	NN	I-NP	O
40	40	CD	B-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
DAILY	DAILY	NN	I-NP	O
HOLD	HOLD	NN	I-NP	O
IF	IF	NN	I-NP	O
:	:	:	O	O
SBP	SBP	NN	B-NP	B-DNA
<	<	SYM	O	I-DNA
90	90	CD	B-NP	I-DNA
DILANTIN	DILANTIN	NN	I-NP	I-DNA
-LRB-	-LRB-	NN	I-NP	I-DNA
PHENYTOIN	PHENYTOIN	NN	I-NP	I-DNA
-RRB-	-RRB-	HYPH	B-NP	I-DNA
230	230	CD	I-NP	I-DNA
MG	MG	NN	I-NP	I-DNA
QAM	QAM	NN	I-NP	I-DNA
;	;	:	O	I-DNA
200	200	CD	B-NP	I-DNA
MG	MG	NN	I-NP	I-DNA
QPM	QPM	NN	I-NP	I-DNA
PO	PO	NN	I-NP	I-DNA
230	230	CD	I-NP	I-DNA
MG	MG	NN	I-NP	I-DNA
QAM	QAM	NN	I-NP	I-DNA
200	200	CD	I-NP	I-DNA
MG	MG	NNP	I-NP	I-DNA
QPM	QPM	NNP	I-NP	I-DNA
Food/Drug	Food/Drug	NNP	I-NP	I-DNA
Interaction	Interaction	NNP	I-NP	I-DNA
Instruction	Instruction	NNP	I-NP	I-DNA
If	If	IN	B-ADJP	O
on	on	IN	B-PP	O
tube	tube	NN	B-NP	O
feeds	feed	NNS	I-NP	O
,	,	,	O	O
please	please	VB	B-VP	O
cycle	cycle	NN	B-NP	B-protein
-LRB-	-LRB-	NN	I-NP	I-protein
hold	hold	VBP	B-VP	O
1	1	CD	B-NP	O
hr	hr	NN	I-NP	O
before	before	IN	B-PP	O
to	to	TO	B-PP	O
2	2	CD	B-NP	O
hr	hr	NN	I-NP	O
after	after	IN	B-PP	O
-RRB-	-RRB-	NN	B-NP	B-DNA
ZOCOR	ZOCOR	NN	I-NP	I-DNA
-LRB-	-LRB-	NN	I-NP	I-DNA
SIMVASTATIN	SIMVASTATIN	NN	I-NP	I-DNA
-RRB-	-RRB-	NN	I-NP	I-DNA
20	20	CD	I-NP	I-DNA
MG	MG	NNP	I-NP	I-DNA
PO	PO	NNP	I-NP	I-DNA
BEDTIME	BEDTIME	NNP	I-NP	I-DNA
Food/Drug	Food/Drug	NNP	I-NP	I-DNA
Interaction	Interaction	NNP	I-NP	I-DNA
Instruction	Instruction	NNP	I-NP	I-DNA
Avoid	Avoid	NNP	I-NP	I-DNA
grapefruit	grapefruit	NN	I-NP	I-DNA
unless	unless	IN	B-SBAR	I-DNA
MD	MD	NN	B-NP	I-DNA
instructs	instruct	NNS	I-NP	I-DNA
otherwise	otherwise	RB	B-ADVP	O
.	.	.	O	O

REPLIVA	REPLIVA	NN	B-NP	O
9/30	9/30	CD	I-NP	O
TABLET	TABLET	NN	I-NP	O
15-200-1	15-200-1	CD	B-NP	O
1	1	CD	I-NP	O
TAB	TAB	NN	I-NP	O
PO	PO	NN	I-NP	O
DAILY	DAILY	NN	I-NP	O
DIET	DIET	NN	I-NP	O
:	:	:	O	O
House	House	NNP	B-NP	O
/	/	SYM	B-NP	O
Low	Low	JJ	I-NP	O
chol/low	chol/low	NN	I-NP	O
sat	sat	NN	I-NP	O
.	.	.	O	O

fat	fat	JJ	B-NP	O
ACTIVITY	ACTIVITY	NN	I-NP	O
:	:	:	O	O
Resume	Resume	VB	B-VP	O
regular	regular	JJ	B-NP	O
exercise	exercise	NN	I-NP	O
FOLLOW	FOLLOW	NNP	I-NP	O
UP	UP	NNP	I-NP	O
APPOINTMENT	APPOINTMENT	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
S	S	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
:	:	:	O	O
Dr.	Dr.	NNP	B-NP	O
Frey	Frey	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
neurologist	neurologist	NN	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
please	please	VB	B-VP	O
call	call	NN	B-NP	O
to	to	TO	B-VP	O
set	set	VB	I-VP	O
up	up	RP	B-PRT	O
within	within	IN	B-PP	O
next	next	JJ	B-NP	O
1-2	1-2	NN	I-NP	O
weeks	week	NNS	I-NP	O
,	,	,	O	O
Dr.	Dr.	NNP	B-NP	O
Kohli	Kohli	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
outpt	outpt	JJ	I-NP	O
pulmonologist	pulmonologist	NN	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Thursday	Thursday	NNP	I-NP	O
October	October	NNP	I-NP	O
,	,	,	O	O
2007	2007	CD	B-NP	O
at	at	IN	B-PP	O
1	1	CD	B-NP	O
:	:	SYM	I-NP	O
40	40	CD	I-NP	O
PM	PM	NN	I-NP	O
scheduled	schedule	VBN	B-VP	O
,	,	,	O	O
Dr.	Dr.	NNP	B-NP	O
Stonewall	Stonewall	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
physician	physician	NN	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
June	June	NNP	I-NP	O
,	,	,	O	O
2007	2007	CD	B-NP	O
scheduled	schedule	VBN	B-VP	O
,	,	,	O	O
ALLERGY	ALLERGY	NN	B-NP	O
:	:	:	O	O
NKA	NKA	NN	B-NP	O
ADMIT	ADMIT	NN	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
:	:	:	O	O
Hypoxemia	Hypoxemia	NNP	B-NP	O
PRINCIPAL	PRINCIPAL	NNP	I-NP	O
DISCHARGE	DISCHARGE	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
;	;	:	O	O
Responsible	Responsible	JJ	B-ADJP	O
After	After	IN	B-PP	O
Study	Study	NNP	B-NP	O
for	for	IN	B-PP	O
Causing	Causing	NNP	B-NP	O
Admission	Admission	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Asthmatic	Asthmatic	NNP	I-NP	O
flare	flare	NN	I-NP	O
OTHER	OTHER	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
;	;	:	O	O
Conditions	Condition	NNS	B-NP	O
,	,	,	O	O
Infections	Infection	NNS	B-NP	O
,	,	,	O	O
Complications	Complication	NNS	B-NP	O
,	,	,	O	O
affecting	affect	VBG	B-VP	O
Treatment/Stay	Treatment/Stay	NNP	B-NP	O
Acute	Acute	NNP	I-NP	O
Asthma	Asthma	NNP	I-NP	O
Flare	Flare	NNP	I-NP	O
OPERATIONS	OPERATIONS	NNS	I-NP	O
AND	AND	CC	I-NP	O
PROCEDURES	PROCEDURES	NNS	I-NP	O
:	:	:	O	O
OTHER	OTHER	NNP	B-NP	O
TREATMENTS/PROCEDURES	TREATMENTS/PROCEDURES	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
NOT	NOT	NNP	I-NP	O
IN	IN	NNP	I-NP	O
O.R.	O.R.	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Echocardiogram	Echocardiogram	NNP	I-NP	O
9/25/07	9/25/07	CD	I-NP	O
BRIEF	BRIEF	NN	I-NP	O
RESUME	RESUME	NN	I-NP	O
OF	OF	IN	B-PP	O
HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
:	:	:	O	O
CC	CC	NN	B-NP	O
:	:	:	O	O
seizures	seizure	NNS	B-NP	O
,	,	,	O	O
hypoxemia	hypoxemia	NN	B-NP	O
HPI	HPI	NN	I-NP	O
:	:	:	O	O
53F	53F	NN	B-NP	O
h/o	h/o	NN	I-NP	O
sarcoid	sarcoid	NN	I-NP	O
,	,	,	O	O
seizure	seizure	NN	B-NP	O
disorder	disorder	NN	I-NP	O
within	within	IN	B-PP	O
the	the	DT	B-NP	O
last	last	JJ	I-NP	O
year	year	NN	I-NP	O
,	,	,	O	O
possible	possible	JJ	B-NP	O
cardiomyopathy	cardiomyopathy	NN	I-NP	O
,	,	,	O	O
asthma	asthma	NN	B-NP	O
,	,	,	O	O
smoking	smoking	NN	B-NP	O
,	,	,	O	O
HTN	HTN	NN	B-NP	B-protein
,	,	,	O	O
and	and	CC	O	O
obesity	obesity	NN	B-NP	O
p/w	p/w	NN	I-NP	O
seizure	seizure	NN	I-NP	O
activity	activity	NN	I-NP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
and	and	CC	O	O
then	then	RB	B-ADVP	O
later	later	RBR	B-ADVP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
ED	ED	NN	I-NP	O
.	.	.	O	O

Has	Has	IN	B-PP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
intermittent	intermittent	JJ	B-NP	O
non-adherence	non-adherence	NN	I-NP	O
to	to	TO	B-PP	O
prescribed	prescribe	VBN	B-NP	O
dilantin	dilantin	NN	I-NP	O
regimen	regimen	NN	I-NP	O
.	.	.	O	O

Treated	Treat	VBN	B-VP	O
acutely	acutely	RB	B-ADVP	O
with	with	IN	B-PP	O
ativan	ativan	NN	B-NP	O
,	,	,	O	O
found	find	VBN	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
subtherapeutic	subtherapeutic	JJ	B-ADJP	O
on	on	IN	B-PP	O
dilantin	dilantin	NN	B-NP	O
so	so	RB	B-ADJP	O
re-loaded	re-loaded	JJ	I-ADJP	O
with	with	IN	B-PP	O
dilantin	dilantin	NN	B-NP	O
to	to	TO	B-VP	O
achieve	achieve	VB	I-VP	O
therapeutic	therapeutic	JJ	B-NP	O
levels	level	NNS	I-NP	O
.	.	.	O	O

Observed	Observe	VBN	B-VP	O
in	in	IN	B-PP	O
ED	ED	VBN	B-VP	O
overnight	overnight	RB	B-ADVP	O
with	with	IN	B-PP	O
plans	plan	NNS	B-NP	O
for	for	IN	B-PP	O
morning	morning	NN	B-NP	O
discharge	discharge	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
became	become	VBD	B-VP	O
questionably	questionably	RB	B-NP	O
hypoxemic	hypoxemic	JJ	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
O2	O2	NN	I-NP	O
sat	sit	VBD	B-VP	O
low	low	JJ	B-NP	O
90s	90	NNS	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
and	and	CC	O	O
somewhat	somewhat	RB	B-ADJP	O
subjectively	subjectively	RB	I-ADJP	O
dyspneic	dyspneic	JJ	I-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
physicians	physician	NNS	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
emergency	emergency	NN	I-NP	O
room	room	NN	I-NP	O
thought	think	VBD	B-VP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
having	have	VBG	I-VP	O
an	an	DT	B-NP	O
asthma	asthma	NN	I-NP	O
exacerbation	exacerbation	NN	I-NP	O
and	and	CC	O	O
gave	give	VBD	B-VP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
prednisone	prednisone	NN	I-NP	O
60mg	60mg	NN	I-NP	O
x	x	NN	I-NP	O
1	1	CD	I-NP	O
,	,	,	O	O
combivent/albuterol	combivent/albuterol	NN	B-NP	O
nebulizer	nebulizer	NN	I-NP	O
treatment	treatment	NN	I-NP	O
,	,	,	O	O
levofloxacin/clindamycin	levofloxacin/clindamycin	NN	B-NP	O
for	for	IN	B-PP	O
possible	possible	JJ	B-NP	O
aspiration	aspiration	NN	I-NP	O
pneumonia	pneumonia	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
admitted	admit	VBD	B-VP	O
her	her	PRP	B-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
medical	medical	JJ	I-NP	O
floor	floor	NN	I-NP	O
for	for	IN	B-PP	O
further	further	JJ	B-NP	O
evaluation	evaluation	NN	I-NP	O
and	and	CC	I-NP	O
treatment	treatment	NN	I-NP	O
.	.	.	O	O

Hospital	Hospital	NNP	B-NP	O
Course	Course	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Pulmonary	Pulmonary	NNP	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
admission	admission	NN	B-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
floor	floor	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
found	find	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
normal	normal	JJ	B-NP	O
oxygen	oxygen	NN	I-NP	O
saturations	saturation	NNS	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
mid	mid	JJ	I-NP	O
90s	90	NNS	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
not	not	RB	I-VP	O
thought	think	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
any	any	DT	B-NP	O
concurrent	concurrent	JJ	I-NP	O
bronchospasm	bronchospasm	NN	I-NP	O
or	or	CC	O	O
focal	focal	JJ	B-NP	O
sounds	sound	NNS	I-NP	O
of	of	IN	B-PP	O
a	a	DT	B-NP	O
pneumonia	pneumonia	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
chest	chest	NN	I-NP	O
x	x	SYM	B-NP	O
ray	ray	NN	I-NP	O
was	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
not	not	RB	I-VP	O
having	have	VBG	I-VP	O
fevers	fever	NNS	B-NP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
white	white	JJ	I-NP	O
blood	blood	NN	I-NP	O
count	count	NN	I-NP	O
was	be	VBD	B-VP	O
normal	normal	JJ	B-ADJP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
steroids	steroid	NNS	I-NP	O
and	and	CC	I-NP	O
levofloxacin/clindamycin	levofloxacin/clindamycin	NN	I-NP	O
were	be	VBD	B-VP	O
therefore	therefore	RB	I-VP	O
discontinued	discontinue	VBN	I-VP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
received	receive	VBD	B-VP	O
her	her	PRP$	B-NP	O
home	home	NN	I-NP	O
inhalers	inhaler	NNS	I-NP	O
and	and	CC	I-NP	O
nebulizers	nebulizer	NNS	I-NP	O
only	only	RB	B-ADVP	O
.	.	.	O	O

She	She	PRP	B-NP	O
remained	remain	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
on	on	IN	B-PP	O
this	this	DT	B-NP	O
regimen	regimen	NN	I-NP	O
throughout	throughout	IN	B-PP	O
her	her	PRP$	B-NP	O
hospital	hospital	NN	I-NP	O
stay	stay	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
breath	breath	NN	I-NP	O
sounds	sound	NNS	I-NP	O
and	and	CC	O	O
heart	heart	NN	B-NP	O
sounds	sound	NNS	I-NP	O
were	be	VBD	B-VP	O
admittedly	admittedly	RB	B-ADVP	O
a	a	DT	B-NP	O
bit	bit	NN	I-NP	O
distant	distant	JJ	B-ADJP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
may	may	MD	B-VP	O
have	have	VB	I-VP	O
an	an	DT	B-NP	O
element	element	NN	I-NP	O
of	of	IN	B-PP	O
undiagnosed	undiagnosed	JJ	B-NP	O
COPD	COPD	NN	I-NP	O
,	,	,	O	O
so	so	RB	O	O
pulmonary	pulmonary	JJ	B-NP	O
function	function	NN	I-NP	O
tests	test	NNS	I-NP	O
were	be	VBD	B-VP	O
recommended	recommend	VBN	I-VP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
.	.	.	O	O

Additionally	Additionally	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
may	may	MD	B-VP	O
benefit	benefit	VB	I-VP	O
from	from	IN	B-PP	O
a	a	DT	B-NP	O
sleep	sleep	JJ	I-NP	O
study	study	NN	I-NP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
given	give	VBN	B-VP	O
her	her	PRP$	B-NP	O
component	component	NN	I-NP	O
of	of	IN	B-PP	O
desaturation	desaturation	NN	B-NP	O
while	while	IN	B-SBAR	O
asymptomatic	asymptomatic	JJ	B-ADJP	O
and	and	CC	O	O
sleeping	sleep	VBG	B-VP	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
night	night	NN	I-NP	O
of	of	IN	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
-RRB-	-RRB-	:	O	O
Infectious	Infectious	JJ	B-NP	O
disease	disease	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
did	do	VBD	B-VP	O
have	have	VB	I-VP	O
an	an	DT	B-NP	O
apparent	apparent	JJ	I-NP	O
urinary	urinary	JJ	I-NP	O
tract	tract	NN	I-NP	O
infection	infection	NN	I-NP	O
and	and	CC	I-NP	O
so	so	NN	I-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
ciprofloxacin	ciprofloxacin	NN	B-NP	O
250mg	250mg	NN	I-NP	O
twice	twice	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
for	for	IN	B-PP	O
three	three	CD	B-NP	O
days	day	NNS	I-NP	O
.	.	.	O	O

3	3	CD	B-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Cardiovascular	Cardiovascular	NNP	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
pt	pt	NN	I-NP	O
did	do	VBD	B-VP	O
report	report	VB	I-VP	O
some	some	DT	B-NP	O
symptoms	symptom	NNS	I-NP	O
of	of	IN	B-PP	O
PND	PND	NN	B-NP	B-protein
and	and	CC	I-NP	O
orthopnea	orthopnea	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
appeared	appear	VBD	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
stable	stable	JJ	B-ADJP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
last	last	JJ	I-NP	O
several	several	JJ	I-NP	O
years	year	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
not	not	RB	O	O
volume	volume	NN	B-NP	O
overloaded	overload	VBN	B-VP	O
on	on	IN	B-PP	O
exam	exam	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
received	receive	VBD	B-VP	O
an	an	DT	B-NP	O
echocardiogram	echocardiogram	NN	I-NP	O
to	to	TO	B-VP	O
investigate	investigate	VB	I-VP	O
possible	possible	JJ	B-NP	O
cardiomyopathy	cardiomyopathy	NN	I-NP	O
or	or	CC	O	O
congestive	congestive	JJ	B-NP	O
failure	failure	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
this	this	DT	B-NP	O
showed	show	VBD	B-VP	O
a	a	DT	B-NP	O
normal	normal	JJ	I-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
without	without	IN	B-PP	O
obvious	obvious	JJ	B-NP	O
structural	structural	JJ	I-NP	O
abnormalities	abnormality	NNS	I-NP	O
except	except	IN	B-PP	O
for	for	IN	B-PP	O
mild	mild	JJ	B-NP	O
bilateral	bilateral	JJ	I-NP	O
atrial	atrial	JJ	I-NP	O
dilatation	dilatation	NN	I-NP	O
.	.	.	O	O

4	4	CD	B-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Neurological	Neurological	NNP	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
inpatient	inpatient	JJ	I-NP	O
medical	medical	JJ	I-NP	O
team	team	NN	I-NP	O
communicated	communicate	VBN	B-VP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
pts	pt	NNS	I-NP	O
outpatient	outpatient	NN	I-NP	O
neurologist	neurologist	NN	I-NP	O
to	to	TO	B-VP	O
discuss	discuss	VB	I-VP	O
continued	continued	JJ	B-NP	O
seizures	seizure	NNS	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
context	context	NN	I-NP	O
of	of	IN	B-PP	O
questionable	questionable	JJ	B-NP	O
intermittent	intermittent	JJ	I-NP	O
noncompliance	noncompliance	NN	I-NP	O
.	.	.	O	O

Per	Per	IN	B-PP	O
the	the	DT	B-NP	O
instructions	instruction	NNS	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
neurologist	neurologist	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
pts	pt	NNS	I-NP	O
dilantin	dilantin	NN	I-NP	O
was	be	VBD	B-VP	O
increased	increase	VBN	I-VP	O
to	to	TO	B-VP	O
230mg	230mg	VB	I-VP	O
PO	PO	NN	B-NP	B-protein
QAM	QAM	NN	I-NP	I-protein
and	and	CC	O	O
200mg	200mg	NN	B-NP	O
PO	PO	NN	I-NP	O
QPM	QPM	NN	I-NP	O
with	with	IN	B-PP	O
plans	plan	NNS	B-NP	O
to	to	TO	B-VP	O
check	check	VB	I-VP	O
another	another	DT	B-NP	O
dilantin	dilantin	NN	I-NP	O
level	level	NN	I-NP	O
on	on	IN	B-PP	O
Friday	Friday	NNP	B-NP	O
March	March	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
five	five	CD	B-NP	O
days	day	NNS	I-NP	O
after	after	IN	B-PP	O
increasing	increase	VBG	B-VP	O
dose	dose	NN	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
.	.	.	O	O

Her	Her	PRP$	B-NP	O
neurontin	neurontin	NN	I-NP	O
dose	dose	NN	I-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
increased	increase	VBN	I-VP	O
to	to	TO	I-VP	O
600mg	600mg	VB	I-VP	O
three	three	CD	B-NP	O
times	time	NNS	I-NP	O
daily	daily	RB	I-NP	O
.	.	.	O	O

ADDITIONAL	ADDITIONAL	JJ	B-NP	O
COMMENTS	COMMENTS	NNS	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
Please	Please	NN	I-NP	O
draw	draw	NN	I-NP	O
dilantin	dilantin	NN	I-NP	O
level	level	NN	I-NP	O
on	on	IN	B-PP	O
Friday	Friday	NNP	B-NP	O
4/3/07	4/3/07	CD	I-NP	O
and	and	CC	O	O
send	send	VB	B-VP	O
results	result	NNS	B-NP	O
to	to	TO	B-PP	O
outpatient	outpatient	JJ	B-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
physician	physician	NN	I-NP	O
and	and	CC	O	O
outpatient	outpatient	NN	B-NP	O
neurologist	neurologist	NN	I-NP	O
.	.	.	O	O

2	2	CD	B-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Please	Please	NNP	I-NP	O
help	help	NN	I-NP	O
pt	pt	NN	I-NP	O
with	with	IN	B-PP	O
medication	medication	NN	B-NP	O
teaching	teaching	NN	I-NP	O
,	,	,	O	O
especially	especially	RB	B-ADVP	O
as	as	IN	B-SBAR	O
regards	regard	NNS	B-NP	O
anti-epileptics	anti-epileptics	JJ	B-NP	B-protein
-LRB-	-LRB-	NN	I-NP	I-protein
dilantin	dilantin	NN	I-NP	I-protein
,	,	,	O	O
neurontin	neurontin	NN	B-NP	B-protein
-RRB-	-RRB-	NN	I-NP	I-protein
in	in	IN	B-SBAR	O
order	order	NN	O	O
to	to	TO	B-VP	O
improve	improve	VB	I-VP	O
outpt	outpt	JJ	B-NP	O
compliance	compliance	NN	I-NP	O
and	and	CC	O	O
reduce	reduce	VB	B-VP	O
frequency	frequency	NN	B-NP	O
of	of	IN	B-PP	O
seizures	seizure	NNS	B-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
CONDITION	CONDITION	NN	I-NP	O
:	:	:	O	O
Stable	Stable	JJ	B-NP	O
TO	TO	NN	I-NP	O
DO/PLAN	DO/PLAN	NN	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Please	Please	NNP	I-NP	O
follow	follow	VB	B-VP	O
up	up	RP	B-PRT	O
dilantin	dilantin	NN	B-NP	O
level	level	NN	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
drawn	draw	VBN	I-VP	O
by	by	IN	B-PP	O
VNA	VNA	NN	B-NP	B-protein
on	on	IN	B-PP	O
Friday	Friday	NNP	B-NP	O
10/21/07	10/21/07	CD	I-NP	O
.	.	.	O	O

2	2	CD	B-NP	O
-RRB-	-RRB-	HYPH	O	O
Consider	Consider	VB	B-VP	O
PFTs/sleep	PFTs/sleep	NN	B-NP	O
study	study	NN	I-NP	O
as	as	IN	B-PP	O
outpt	outpt	NN	B-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
dictated	dictated	JJ	I-NP	O
summary	summary	NN	I-NP	O
ENTERED	ENTERED	NNP	I-NP	O
BY	BY	NNP	I-NP	O
:	:	:	O	O
ANCELL	ANCELL	NNP	B-NP	O
,	,	,	O	O
JR	JR	NNP	B-NP	O
,	,	,	O	O
GIUSEPPE	GIUSEPPE	NNP	B-NP	O
W.	W.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
ES28	ES28	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
3/26/07	3/26/07	CD	I-NP	O
@	@	SYM	B-NP	O
04	04	CD	I-NP	O
******	******	SYM	I-NP	O
END	END	NN	I-NP	O
OF	OF	IN	B-PP	O
DISCHARGE	DISCHARGE	NN	B-NP	O
ORDERS	ORDERS	NNS	I-NP	O
******	******	SYM	B-NP	O

